scispace - formally typeset
G

Georg Emons

Researcher at University of Göttingen

Publications -  21
Citations -  1018

Georg Emons is an academic researcher from University of Göttingen. The author has contributed to research in topics: Colorectal cancer & Cancer. The author has an hindex of 10, co-authored 19 publications receiving 843 citations.

Papers
More filters
Journal ArticleDOI

Mutated KRAS results in overexpression of DUSP4, a MAP-kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomas.

TL;DR: Findings suggest a potential approach to overcome resistance to treatment with antibodies against the epithelial growth factor receptor in patients with KRAS‐mutant rectal carcinomas.
Journal ArticleDOI

Impact of RNA degradation on gene expression profiling

TL;DR: Degraded RNA from tumor samples (RIN > 5) can still be used to perform gene expression analysis, but there are genes, very short ones and those with the probe binding side close to the 5' end that should be excluded from gene expressionAnalysis when working with degraded RNA.
Journal ArticleDOI

STAT3 inhibition sensitizes colorectal cancer to chemoradiotherapy in vitro and in vivo

TL;DR: Results highlight a potential role of STAT3 in mediating treatment resistance and provide first proof of concept that STAT3 represents a promising novel molecular target for sensitizing resistant rectal cancers to CT/RT.
Journal ArticleDOI

Chemoradiotherapy Resistance in Colorectal Cancer Cells is Mediated by Wnt/β-catenin Signaling.

TL;DR: Aberrant activation of Wnt/β-catenin signaling not only regulates the development and progression of colorectal cancer, but also mediates resistance of rectal cancers to chemoradiotherapy.
Journal ArticleDOI

Silencing of the Wnt transcription factor TCF4 sensitizes colorectal cancer cells to (chemo-) radiotherapy

TL;DR: Results suggest that TCF4 is a promising molecular target to sensitize resistant tumor cells to (chemo-) radiotherapy, and indicate a novel mechanism through which the Wnt transcription factor TCF 4 mediates chemoradioresistance.